碘131治疗甲亢所致甲减危险因素分析  

Analysis of Risk Factors of Hypothyroidism Caused by Hyperthyroidism for Iodine 131 Treatment

作　　者：张秀坤[1] 于淼[1] 齐伟[1] 齐波[1] 王波[1] 徐明艳[1] 邹香妮[1] 

机构地区：[1]黑龙江省医院南岗分院,哈尔滨150001

出　　处：《中国卫生标准管理》2016年第2期98-99,共2页China Health Standard Management

摘　　要：目的研究分析甲亢患者接受碘131治疗的临床危险因素。方法根据2012年6月-2014年5月我院的84例甲亢患者进行研究分析,根据治疗后是否发生甲减,我们将这些患者分成对照组和观察组,对照组为治疗后未发生甲减,观察组为治疗后发生甲减,对他们的临床治疗资料进行回顾分析。结果患者接受碘131治疗后,观察组的血清TPOAb、TGAb、甲状腺质量阳性率要比对照组高,结果差异有统计学意义（P〈0.05）。结论甲亢患者接受碘131治疗时,容易出现甲减症状,所以在治疗过程中,应该要合理的调整剂量,避免甲减出现。Objective To study the clinical risk factors of 131 iodine therapy in patients with hyperthyroidism. Methods According to the analysis of 84 cases of hyperthyroidism in our hospital from June 2012 to May 2014,depending on whether hypothyroidism after treatment,we divided them into two groups,control group and observation group. The clinical data of them were analyzed retrospectively. Results After patients received 131 I treatment,the observation group of serum TPOAb, TGAb,thyroid mass positive rate were higher than the control group. The results showed significant difference（P〈0.05）. Conclusion Patients with hyperthyroidism undergoing 131 I therapy,it is easy to appear the symptoms of hypothyroidism,so the treatment should adjust reasonable dosage to avoid the hypothyroidism.

关 键 词：碘131 甲亢后甲减 危险因素 

分 类 号：R581.1[医药卫生—内分泌]